Bristol Myers Squibb (BMY) Receivables - Net (2009 - 2026)

Bristol Myers Squibb has disclosed Receivables - Net across 18 years of filings, most recently posting $9.4 billion for Q1 2026.

• In Q1 2026, Receivables - Net fell 13.27% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (down 13.27% YoY), while the FY2025 annual figure was $11.4 billion, up 6.21% from the prior year.
• Receivables - Net fell to $9.4 billion in Q1 2026, from $11.4 billion in the prior quarter.
• Over the last five years, Receivables - Net for BMY reached as high as $11.4 billion in Q2 2024 and fell as low as $8.5 billion in Q1 2022.
• The 5-year median for Receivables - Net is $10.4 billion (2024), against an average of $10.4 billion.
• Annual changes were most pronounced in 2023 — Receivables - Net rose 18.13% — and 2026, when it dropped 13.27%.
• A 5-year view of Receivables - Net shows it stood at $9.9 billion in 2022, then rose by 10.47% to $10.9 billion in 2023, then slipped by 1.59% to $10.7 billion in 2024, then climbed by 6.21% to $11.4 billion in 2025, then slipped by 17.93% to $9.4 billion in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $9.4 billion, $11.4 billion, and $11.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.